Alexandra Hickey, Chaonan Dong, Christopher A. Lamb
{"title":"Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer","authors":"Alexandra Hickey, Chaonan Dong, Christopher A. Lamb","doi":"10.1111/apt.70442","DOIUrl":"https://doi.org/10.1111/apt.70442","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"136 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice","authors":"Emma P. Halmos, Peter R. Gibson","doi":"10.1111/apt.70452","DOIUrl":"https://doi.org/10.1111/apt.70452","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"15 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter: Affirming Cardiac Safety While Highlighting Areas for Further Research","authors":"Shanshan Huang, Jie Zhou","doi":"10.1111/apt.70387","DOIUrl":"https://doi.org/10.1111/apt.70387","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"17 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>Resmetirom, an oral selective thyroid hormone receptor beta agonist, is the first pharmacological agent approved by the Food and Drug Administration (FDA) of the United States in 2024 for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stages F2 and F3. In the ongoing, registrational phase 3 MAESTRO-NASH study, the administration of resmetirom for 52 weeks led to MASH resolution and significant improvement in fibrosis by at least one stage as compared to placebo [<span>1</span>]. However, there remains a dearth of information about combining resmetirom with medications that are recommended for treating comorbidities of metabolic dysfunction-associated steatotic liver disease (MASLD), such as glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes (T2D) with and without obesity [<span>2, 3</span>]. Notably, around half of T2D patients have MASH [<span>4</span>]. Therefore, the prespecified analysis of MAESTRONASH by Noureddin et al. has provided timely evidence that in T2D patients, the efficacy of resmetirom on MASH end points was not affected by the stable background use of GLP1RA or SGLT2i [<span>5</span>], which are now commonly prescribed due to their established independent cardiovascular and kidney benefits.</p><p>Both GLP1RA and SGLT2i have been shown to resolve and improve MASH in the recent Effect of Semaglutide in Subjects with Non-cirrhotic non-alcoholic steatohepatitis (ESSENCE) and Dapagliflozin Efficacy and Action in Non-alcoholic steatohepatitis (DEAN) trials, respectively, but residual risk remains [<span>6, 7</span>]. Indeed, in around 40% of the T2D participants from the MAESTRONASH trial, at baseline, their MASH remained present despite the use of either GLP1RA or SGLT2i for a reasonable period (median duration 660 days for GLP1RA and 651 days for SGLT2i) [<span>5</span>]. Although the GLP1RA used were mostly liraglutide, dulaglutide and semaglutide 1 mg weekly instead of semaglutide 2.4 mg weekly as in the ESSENCE trial, it reinforces the need to combine pharmacotherapies to target the different pathophysiological pathways in MASH [<span>8</span>].</p><p>The authors also demonstrated that resmetirom-treated participants who had weight loss ≥ 5%, as compared to those without, showed higher rates of MASH resolution and fibrosis improvement [<span>5</span>]. Further studies should be conducted to investigate if the sequence of initiating these MASH pharmacotherapies matters, for instance, whether starting GLP1RA after resmetirom can enhance its effect through inducing weight loss. Moreover, as several new incretin co-agonists such as tirzepatide, a GLP1- and glucose-dependent insulinotropic polypeptide (GIP) receptors co-agonist, as well as survodutide, a GLP1- and glucagon receptors co-agonist, with more potent weight-reducing effects, have also been shown to improve MASH in phase 2 trials [<span>9,
{"title":"Editorial: An Important Step Towards Mastering Metabolic Dysfunction-Associated Steatohepatitis-Targeted Therapy in Diabetes","authors":"Johnny Yau-Cheung Chang, Chi-Ho Lee","doi":"10.1111/apt.70401","DOIUrl":"10.1111/apt.70401","url":null,"abstract":"<p>Resmetirom, an oral selective thyroid hormone receptor beta agonist, is the first pharmacological agent approved by the Food and Drug Administration (FDA) of the United States in 2024 for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stages F2 and F3. In the ongoing, registrational phase 3 MAESTRO-NASH study, the administration of resmetirom for 52 weeks led to MASH resolution and significant improvement in fibrosis by at least one stage as compared to placebo [<span>1</span>]. However, there remains a dearth of information about combining resmetirom with medications that are recommended for treating comorbidities of metabolic dysfunction-associated steatotic liver disease (MASLD), such as glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes (T2D) with and without obesity [<span>2, 3</span>]. Notably, around half of T2D patients have MASH [<span>4</span>]. Therefore, the prespecified analysis of MAESTRONASH by Noureddin et al. has provided timely evidence that in T2D patients, the efficacy of resmetirom on MASH end points was not affected by the stable background use of GLP1RA or SGLT2i [<span>5</span>], which are now commonly prescribed due to their established independent cardiovascular and kidney benefits.</p><p>Both GLP1RA and SGLT2i have been shown to resolve and improve MASH in the recent Effect of Semaglutide in Subjects with Non-cirrhotic non-alcoholic steatohepatitis (ESSENCE) and Dapagliflozin Efficacy and Action in Non-alcoholic steatohepatitis (DEAN) trials, respectively, but residual risk remains [<span>6, 7</span>]. Indeed, in around 40% of the T2D participants from the MAESTRONASH trial, at baseline, their MASH remained present despite the use of either GLP1RA or SGLT2i for a reasonable period (median duration 660 days for GLP1RA and 651 days for SGLT2i) [<span>5</span>]. Although the GLP1RA used were mostly liraglutide, dulaglutide and semaglutide 1 mg weekly instead of semaglutide 2.4 mg weekly as in the ESSENCE trial, it reinforces the need to combine pharmacotherapies to target the different pathophysiological pathways in MASH [<span>8</span>].</p><p>The authors also demonstrated that resmetirom-treated participants who had weight loss ≥ 5%, as compared to those without, showed higher rates of MASH resolution and fibrosis improvement [<span>5</span>]. Further studies should be conducted to investigate if the sequence of initiating these MASH pharmacotherapies matters, for instance, whether starting GLP1RA after resmetirom can enhance its effect through inducing weight loss. Moreover, as several new incretin co-agonists such as tirzepatide, a GLP1- and glucose-dependent insulinotropic polypeptide (GIP) receptors co-agonist, as well as survodutide, a GLP1- and glucagon receptors co-agonist, with more potent weight-reducing effects, have also been shown to improve MASH in phase 2 trials [<span>9, ","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"63 1","pages":"165-166"},"PeriodicalIF":6.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’","authors":"Chao Zhao","doi":"10.1111/apt.70441","DOIUrl":"https://doi.org/10.1111/apt.70441","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"191 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply","authors":"Monica E. W. Derks, Frank Hoentjen","doi":"10.1111/apt.70473","DOIUrl":"https://doi.org/10.1111/apt.70473","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"18 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, Jing Yi Leong, Wah Loong Chan, Xin Hui Khoo, Kim Leng Wong, Sarala Panirsheeluam, Vicraman Natarajan, Ai Kah Ng, Hazreen Abdul Majid, Sanjiv Mahadeva
{"title":"Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply","authors":"Kee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, Jing Yi Leong, Wah Loong Chan, Xin Hui Khoo, Kim Leng Wong, Sarala Panirsheeluam, Vicraman Natarajan, Ai Kah Ng, Hazreen Abdul Majid, Sanjiv Mahadeva","doi":"10.1111/apt.70469","DOIUrl":"https://doi.org/10.1111/apt.70469","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"18 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：